Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NNMT | P40261 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.44 |
| ▸ | TUBB | P07437 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19808909 | 0.84 | TUBB4A (0.51) | SMN1; SMN2ALDH1A1KDM4EL3MBTL1TUBB4A | |
| SCHEMBL1300585 | 0.84 | TDP1 (0.66) | POLBTDP1NNMTRAB9ANPC1 | |
| SCHEMBL16025487 | 0.84 | POLB (0.51) | POLBTDP1NNMTRAB9ANPC1 | |
| SCHEMBL10008168 | 0.84 | POLB (0.51) | POLBTDP1NNMTRAB9ANPC1 | |
| SCHEMBL5121653 | 0.83 | RAB9A (0.41) | RAB9ANPC1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL31618804 | 0.83 | NNMT (0.47) | POLBTDP1NNMTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5114620 | 0.83 | TDP1 (0.43) | TDP1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL31042446 | 0.82 | SMN1; SMN2 (0.40) | POLBTDP1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL22717309 | 0.82 | SMN1; SMN2 (0.45) | RAB9ANPC1SMN1; SMN2ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL10008289 | 0.82 | TDP1 (0.64) | POLBTDP1NNMTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103475-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORP (US) | 2026-04-16 | — | — | US | disclosed |
| WO-2025202022-A9 | ANTICANCER MACROCYCLIC QUINAZOLINE-BASED INHIBITORS OF THE INERACTION BETWEEN RAS AND SOS1 | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-26 | — | — | WO | disclosed |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFLECTION THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2025202022-A1 | ANTICANCER MACROCYCLIC QUINAZOLINE-BASED INHIBITORS OF THE INERACTION BETWEEN RAS AND SOS1 | BAYER AKTIENGESELLSCHAFT (DE) | 2025-10-02 | — | — | WO | disclosed |
| US-20250154147-A1 | NOVEL AMINE-SUBSTITUTED PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2025-05-15 | — | — | US | disclosed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| CN-119859155-A | Tri-fused ring derivative inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-04-22 | — | — | CN | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| CN-115279771-B | MAP4K1 inhibitors | 缆图药品公司 | 2025-03-21 | — | — | CN | disclosed |
| US-12202844-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| WO-2008076425-A1 | AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076425-A1 | AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1922307-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | disclosed |
| WO-2007044084-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| EP-1682138-A4 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1682138-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050250782-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-10 | — | — | US | disclosed |
| WO-2005051301-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202844-B2 | MAP4K1 inhibitors | MAP4K1, MAP4K4, MAP4K2 | POLB 2761/4885TDP1 756/4885NNMT 1397/4885 |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | POLB 1349/4885TDP1 912/4885NNMT 1790/4885 |
| US-20050250782-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | POLB 1554/4885TDP1 924/4885NNMT 2150/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | POLB 4513/4885TDP1 3446/4885NNMT 1650/4885 |
| US-20260103475-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K4 | POLB 3883/4885TDP1 1722/4885NNMT 1872/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | POLB 3210/4885TDP1 4684/4885NNMT 1606/4885 |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | POLB 1732/4885TDP1 929/4885NNMT 2169/4885 |
| US-20250154147-A1 | NOVEL AMINE-SUBSTITUTED PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOS2, SOST | POLB 3260/4885TDP1 1812/4885NNMT 3198/4885 |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | SUB1, AHR, NCOA3 | POLB 1273/4885TDP1 1293/4885NNMT 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.